Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
Pazina T, MacFarlane AW 4th, Bernabei L, Dulaimi E, Kotcher R, Yam C, Bezman NA, Robbins MD, Ross EA, Campbell KS, Cohen AD. Pazina T, et al. Among authors: ross ea. Cancers (Basel). 2021 Jan 10;13(2):226. doi: 10.3390/cancers13020226. Cancers (Basel). 2021. PMID: 33435153 Free PMC article.
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations.
Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Tsichlis N, Li YS, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman BM, Crowell JA, Kopelovich L, Knudson AG. Stoyanova R, et al. Among authors: ross ea. Cancer Biol Ther. 2004 Dec;3(12):1313-21. doi: 10.4161/cbt.3.12.1459. Epub 2004 Dec 9. Cancer Biol Ther. 2004. PMID: 15662135
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.
Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG. Bellacosa A, et al. Cancer Prev Res (Phila). 2010 Jan;3(1):48-61. doi: 10.1158/1940-6207.CAPR-09-0078. Cancer Prev Res (Phila). 2010. PMID: 20051372 Free PMC article.
Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation.
Peri S, Caretti E, Tricarico R, Devarajan K, Cheung M, Sementino E, Menges CW, Nicolas E, Vanderveer LA, Howard S, Conrad P, Crowell JA, Campbell KS, Ross EA, Godwin AK, Yeung AT, Clapper ML, Uzzo RG, Henske EP, Ricketts CJ, Vocke CD, Linehan WM, Testa JR, Bellacosa A, Kopelovich L, Knudson AG. Peri S, et al. Among authors: ross ea. Oncotarget. 2017 Mar 14;8(11):17628-17642. doi: 10.18632/oncotarget.12192. Oncotarget. 2017. PMID: 27682873 Free PMC article.
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Wagner J, et al. Among authors: ross ea. J Clin Invest. 2018 Jun 1;128(6):2325-2338. doi: 10.1172/JCI96711. Epub 2018 Apr 30. J Clin Invest. 2018. PMID: 29533922 Free PMC article.
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK, Zain J, MacFarlane AW 4th, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Barta SK, et al. Among authors: ross ea. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31029646 Free PMC article. Clinical Trial.
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Miron B, Hoffman-Censits JH, Anari F, O'Neill J, Geynisman DM, Zibelman MR, Kutikov A, Viterbo R, Greenberg RE, Chen D, Lallas CD, Trabulsi EJ, Alpaugh RK, Dulaimi E, Golemis EA, Uzzo R, Ross EA, Plimack ER. Miron B, et al. Among authors: ross ea. Eur Urol Oncol. 2020 Aug;3(4):544-547. doi: 10.1016/j.euo.2020.02.003. Epub 2020 Mar 10. Eur Urol Oncol. 2020. PMID: 32165095 Free PMC article.
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Plimack ER, et al. Among authors: ross ea. J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12. J Clin Oncol. 2014. PMID: 24821881 Free PMC article. Clinical Trial.
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Plimack ER, et al. Among authors: ross ea. Eur Urol. 2015 Dec;68(6):959-67. doi: 10.1016/j.eururo.2015.07.009. Epub 2015 Aug 1. Eur Urol. 2015. PMID: 26238431 Free PMC article.
241 results